US drugmaker Bristol-Myers Squibb and a subsidiary have agreed to pay more than $515m (£251.7m) to settle allegations of marketing certain drugs illegally.
The fines issued by the US Department of Justice mark the end of a probe into the firm’s drug pricing practices that began a number of years ago
Two former directors of US drug company Bristol-Myers Squibb are been sued for civil damages after being accused of masterminding a $1.5bn ($833m) fraud.
The Securities and Exchange Commission watchdog alleges that Frederick Schiff and Richard Lane devised a scheme to inflate sales and profits at the firm
US drugs company Bristol-Myers Squibb has agreed to pay $300m (£165m) into a shareholders’ fund, as prosecutors charged two former executives.
The firm and executives were accused of a practice called “channel stuffing” – offering incentives to get wholesalers to buy more of the company’s products.
The scheme boosted earnings at the firm, which has now agreed a “deferred prosecution” with Newark lawmakers
US drugs firm Bristol-Myers Squibb will pay $150m (£82m) to settle civil fraud charges in one of the biggest settlements in US corporate history.
The Securities and Exchange Commission (SEC) has charged the firm with improperly booking $1.5m in revenue